About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Skin Patch Shows Promising Results in Early Trial

by Julia Samuel on November 15, 2017 at 6:22 PM
Font : A-A+

Skin Patch Shows Promising Results in Early Trial

A skin patch that delivered a high dose of peanut protein reduced peanut sensitivity in children and adults with peanut allergy.

Peanut immunotherapy with a pill isn't especially effective and carries the risk of triggering allergy just as eating a peanut would. Skin patch immunotherapy may have the potential for more safely and effectively treating peanut allergy.

Advertisement


The trial was done in 221 peanut-allergic patients (age 6-55 years).

When: Phase 2b trial: July 31, 2012 - July 31, 2014. Extension: Patients completing the trial participated in a 2-year extension using the most effective peanut-patch dose to assess efficacy for up to 36 months; extension study completed September 29, 2016.
Advertisement

What (Study Measures): The percentage of treatment responders in each group vs placebo patch after 12 months. Patients were considered treatment responders if it took 1,000 mg or more of peanut protein and/or 10-times the pretreatment amount of peanuts to trigger an allergic reaction.

How (Study Design): This was a phase 2b clinical trial that randomly assigned participants to a peanut patch containing 50 μg, 100 μg or 250 μg of peanut protein or placebo for 12 months. Phase 2b trials confirm the efficacy of an intervention and determine the most effective dose and are typically followed by a phase 3 trial in a broader population.

Randomized clinical trials (RCTs) allow for the strongest inferences to be made about the true effect of an intervention such as a medication or a procedure. However, not all RCT results can be replicated in real-world settings because patient characteristics or other variables may differ from those that were studied in the RCT.

Results: There were more treatment responders among patients given the 250-μg peanut patch (n = 28; 50 percent) than among patients given the placebo patch (n = 14; 25 percent). There was no difference between the placebo and 100-μg patch. The percentage of patients with one or more treatment-emergent adverse events (largely local skin reactions) was similar across all groups in year 1.

Study Limitations: The primary endpoint (10-times increase in challenge threshold) may not have been sufficiently stringent for the lowest food challenge doses, which contributed to the higher-than-expected rate of placebo responders.

The sample size of each treatment group was relatively small and therefore, the study was not powered to detect a dose-response gradient.

Study Conclusions: These findings support testing of the 250-μg peanut patch dose in a phase 3 trial involving patients with peanut allergy.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Boils / Skin Abscess Pityriasis rosea Pemphigus Hives Scleroderma Vitiligo Skin Self Examination Actinic Keratosis Dermatomyostitis 

Recommended Reading
Types of Food Allergies
If you are allergic to certain food items-Watch out for what you eat...
Clinical Guidelines to Prevent & Deal With Peanut Allergy
Emerging data suggests that peanut allergy can be prevented by the early introduction of ......
Childhood Peanut Allergy Increases by 21 Percent
Peanut allergies have increased by 21 percent in children. Parents can prevent the allergy by ......
Peanut Allergy Prevention Strategy is Nutritionally Safe: NIH
Learning Early About Peanut Allergy (LEAP) clinical trial provide reassurance that early-life ......
Actinic Keratosis
Actinic Keratosis or Solar Keratosis is a pre-cancerous condition characterized by thick, rough, dry...
Boils / Skin Abscess
Encyclopedia section of medindia gives general info about Boils / Skin Abscess ...
Dermatomyostitis
Dermatomyostitis (DM) is an uncommon, inflammatory disease affecting the connective tissues. It is c...
Hives
Hives or Urticaria are allergic skin reaction that appear suddenly in clusters or as single bumps on...
Pemphigus
Pemphigus is a rare group of autoimmune diseases that affect the skin and mucous membranes causing b...
Pityriasis Rosea
Pityriasis rosea is a common skin disease that is not contagious. It manifests as oval-shaped, pink ...
Scleroderma
Scleroderma or CREST syndrome is a chronic, auto immune disease which manifests as thick, dry, fibro...
Skin Self Examination
The skin self examination means checking one’s own skin for any visible abnormal growths or unusual ...
Vitiligo
Vitiligo is a skin disease characterized by patches of unpigmented skin. Vitiligo is usually slowly ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use